Publications
Landmark Studies
KOAR is a large real-world registry of kidney transplant outcomes, tracking over 1,700 patients across 56 centers. This pivotal study demonstrated that AlloSure donor-derived cell-free DNA testing enables earlier detection of rejection and was shown to improve biopsy yield.
Bromberg, Kothari. dd-cfDNA Significantly Improves Rejection Yield in Kidney Transplant Biopsies. American Journal of Transplantation. 2025
1,743 patients across 56 transplant centers
Largest international real world kidney transplant study evaluating dd-cfDNA
Elevated AlloSure® detected rejection risk up to 4 months before biopsy
4x higher likelihood of detecting rejection on for-cause biopsies in patients with elevated AlloSure®
6x higher likelihood of detecting rejection on surveillance biopsies in patients with elevated AlloSure®
SHORE, a landmark, prospective, observational, multicenter registry in heart transplant. The pivotal study demonstrated the clinical utility and prognostic value of HeartCare.
Teuteberg, Uriel. Multimodal Molecular Testing Provides Prognostic Value for Heart Transplant Recipients . Journal of Heart and Lung Transplantation. 2025
Khush, Teuteberg. Surveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: Outcomes from the Surveillance HeartCare Outcomes Registry. Journal of Heart and Lung Transplantation. 2024
2,732 transplant patients across 67 transplants centers in United States since 2018
97.3% of patients monitored with HeartCare had normal graft function at 2 yrs
Patients monitored with HeartCare had a 94.9% survival rate at 2 years
Patients with AlloMap(+) AlloSure(+) are 6x more likely to have biopsy confirmed ACR compared to -/- result.
Patients with AlloMap(+) AlloSure(+) were ~2X more likely to experience poor outcomes, even in absence of histological rejection.
This peer-reviewed study in Nature Medicine validated AlloSure® as a powerful, noninvasive tool for early detection of kidney transplant rejection.
Aubert, Loupy. Cell-free DNA for the detection of kidney allograft rejection. Nature Medicine. 2024
AlloSure improved rejection detection across clinical scenarios and timepoints post-transplant
AlloSure is highly associated with the severity of all types of rejection
Reinforced confidence in molecular surveillance